Immunic (IMUX) announced the appointment of Michael Panzara as chief medical officer, effective April 24. Panzara will lead the company’s development organization, including clinical development, medical affairs, and regulatory affairs, and will be a partner to the CEO and the board of directors in defining and driving the overall company strategy. Panzara succeeds Andreas Muehler. Panzara most recently served as chief medical officer of Neurvati Neurosciences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX: